Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection

Alessandra Biffi, Cynthia C. Bartholomae, Daniela Cesana, Natalie Cartier, Patrik Aubourg, Marco Ranzani, Martina Cesani, Fabrizio Benedicenti, Tiziana Plati, Enrico Rubagotti, Stefania Merella, Alessia Capotondo, Jacopo Sgualdino, Gianluigi Zanetti, Christof Von Kalle, Manfred Schmidt, Luigi Naldini, Eugenio Montini

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

A recent clinical trial for adrenoleukodystrophy (ALD) showed the efficacy and safety of lentiviral vector (LV) gene transfer in hematopoietic stem progenitor cells. However, several common insertion sites (CIS) were found in patients' cells, suggesting that LV integrations conferred a selective advantage. We performed highthroughput LV integration site analysis on human hematopoietic stem progenitor cells engrafted in immunodeficient mice and found the same CISs reported in patients with ALD. Strikingly, most CISs in our experimental model and in patients with ALD cluster in megabase-wide chromosomal regions of high LV integration density. Conversely, cancer-triggering integrations at CISs found in tumor cells from γretroviral vector-based clinical trials and oncogene-tagging screenings in mice always target a single gene and are contained in narrow genomic intervals. These findings imply that LV CISs are produced by an integration bias toward specific genomic regions rather than by oncogenic selection.

Original languageEnglish
Pages (from-to)5332-5339
Number of pages8
JournalBlood
Volume117
Issue number20
DOIs
Publication statusPublished - May 19 2011

Fingerprint

Adrenoleukodystrophy
Hematopoietic Stem Cells
Clinical Trials
Stem cells
Oncogenes
Genes
Gene transfer
Neoplasms
Theoretical Models
Safety
Tumors
Screening
Cells

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. / Biffi, Alessandra; Bartholomae, Cynthia C.; Cesana, Daniela; Cartier, Natalie; Aubourg, Patrik; Ranzani, Marco; Cesani, Martina; Benedicenti, Fabrizio; Plati, Tiziana; Rubagotti, Enrico; Merella, Stefania; Capotondo, Alessia; Sgualdino, Jacopo; Zanetti, Gianluigi; Von Kalle, Christof; Schmidt, Manfred; Naldini, Luigi; Montini, Eugenio.

In: Blood, Vol. 117, No. 20, 19.05.2011, p. 5332-5339.

Research output: Contribution to journalArticle

Biffi, A, Bartholomae, CC, Cesana, D, Cartier, N, Aubourg, P, Ranzani, M, Cesani, M, Benedicenti, F, Plati, T, Rubagotti, E, Merella, S, Capotondo, A, Sgualdino, J, Zanetti, G, Von Kalle, C, Schmidt, M, Naldini, L & Montini, E 2011, 'Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection', Blood, vol. 117, no. 20, pp. 5332-5339. https://doi.org/10.1182/blood-2010-09-306761
Biffi, Alessandra ; Bartholomae, Cynthia C. ; Cesana, Daniela ; Cartier, Natalie ; Aubourg, Patrik ; Ranzani, Marco ; Cesani, Martina ; Benedicenti, Fabrizio ; Plati, Tiziana ; Rubagotti, Enrico ; Merella, Stefania ; Capotondo, Alessia ; Sgualdino, Jacopo ; Zanetti, Gianluigi ; Von Kalle, Christof ; Schmidt, Manfred ; Naldini, Luigi ; Montini, Eugenio. / Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. In: Blood. 2011 ; Vol. 117, No. 20. pp. 5332-5339.
@article{403799d43cef4b36935c178f77c6f1ae,
title = "Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection",
abstract = "A recent clinical trial for adrenoleukodystrophy (ALD) showed the efficacy and safety of lentiviral vector (LV) gene transfer in hematopoietic stem progenitor cells. However, several common insertion sites (CIS) were found in patients' cells, suggesting that LV integrations conferred a selective advantage. We performed highthroughput LV integration site analysis on human hematopoietic stem progenitor cells engrafted in immunodeficient mice and found the same CISs reported in patients with ALD. Strikingly, most CISs in our experimental model and in patients with ALD cluster in megabase-wide chromosomal regions of high LV integration density. Conversely, cancer-triggering integrations at CISs found in tumor cells from γretroviral vector-based clinical trials and oncogene-tagging screenings in mice always target a single gene and are contained in narrow genomic intervals. These findings imply that LV CISs are produced by an integration bias toward specific genomic regions rather than by oncogenic selection.",
author = "Alessandra Biffi and Bartholomae, {Cynthia C.} and Daniela Cesana and Natalie Cartier and Patrik Aubourg and Marco Ranzani and Martina Cesani and Fabrizio Benedicenti and Tiziana Plati and Enrico Rubagotti and Stefania Merella and Alessia Capotondo and Jacopo Sgualdino and Gianluigi Zanetti and {Von Kalle}, Christof and Manfred Schmidt and Luigi Naldini and Eugenio Montini",
year = "2011",
month = "5",
day = "19",
doi = "10.1182/blood-2010-09-306761",
language = "English",
volume = "117",
pages = "5332--5339",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection

AU - Biffi, Alessandra

AU - Bartholomae, Cynthia C.

AU - Cesana, Daniela

AU - Cartier, Natalie

AU - Aubourg, Patrik

AU - Ranzani, Marco

AU - Cesani, Martina

AU - Benedicenti, Fabrizio

AU - Plati, Tiziana

AU - Rubagotti, Enrico

AU - Merella, Stefania

AU - Capotondo, Alessia

AU - Sgualdino, Jacopo

AU - Zanetti, Gianluigi

AU - Von Kalle, Christof

AU - Schmidt, Manfred

AU - Naldini, Luigi

AU - Montini, Eugenio

PY - 2011/5/19

Y1 - 2011/5/19

N2 - A recent clinical trial for adrenoleukodystrophy (ALD) showed the efficacy and safety of lentiviral vector (LV) gene transfer in hematopoietic stem progenitor cells. However, several common insertion sites (CIS) were found in patients' cells, suggesting that LV integrations conferred a selective advantage. We performed highthroughput LV integration site analysis on human hematopoietic stem progenitor cells engrafted in immunodeficient mice and found the same CISs reported in patients with ALD. Strikingly, most CISs in our experimental model and in patients with ALD cluster in megabase-wide chromosomal regions of high LV integration density. Conversely, cancer-triggering integrations at CISs found in tumor cells from γretroviral vector-based clinical trials and oncogene-tagging screenings in mice always target a single gene and are contained in narrow genomic intervals. These findings imply that LV CISs are produced by an integration bias toward specific genomic regions rather than by oncogenic selection.

AB - A recent clinical trial for adrenoleukodystrophy (ALD) showed the efficacy and safety of lentiviral vector (LV) gene transfer in hematopoietic stem progenitor cells. However, several common insertion sites (CIS) were found in patients' cells, suggesting that LV integrations conferred a selective advantage. We performed highthroughput LV integration site analysis on human hematopoietic stem progenitor cells engrafted in immunodeficient mice and found the same CISs reported in patients with ALD. Strikingly, most CISs in our experimental model and in patients with ALD cluster in megabase-wide chromosomal regions of high LV integration density. Conversely, cancer-triggering integrations at CISs found in tumor cells from γretroviral vector-based clinical trials and oncogene-tagging screenings in mice always target a single gene and are contained in narrow genomic intervals. These findings imply that LV CISs are produced by an integration bias toward specific genomic regions rather than by oncogenic selection.

UR - http://www.scopus.com/inward/record.url?scp=79954733266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954733266&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-09-306761

DO - 10.1182/blood-2010-09-306761

M3 - Article

VL - 117

SP - 5332

EP - 5339

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -